Parmax Pharma
Healthcare
540359 BSE
₹133.70
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Close 2 Nov 2026 ₹133.70 +100.70 +305% 1Y
Start ₹33.00
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- −76.60%
- Debt to Equity
- Not meaningful: shareholders’ equity is negative
- EPS (TTM)
- −₹3.18
- Book Value
- —
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- Not meaningful: book value is negative
- ROE
- Not meaningful: shareholders’ equity is negative
- Dividend Yield
- 0.00%
- EBITDA
- −₹3.60 Cr
- 52W High
- ₹139.10
- 52W Low
- ₹22.60
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
40 Weak
Data confidence 86/100
Category scores
- Quality
- 16
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 31
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 17
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 15
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 99
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 65
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Promoter holding has increased by 33.9% over last quarter.
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -14.3% over past five years.
- Debtor days have increased from 57.4 to 95.2 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 4 | 4 | 11 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bullish | 2 | 0 | 8 |
Oscillators
Bullish
Bearish
2
Neutral
4
Bullish
3
Overall
Strong Bullish
Bearish
4
Neutral
4
Bullish
11
Moving Averages
Strong Bullish
Bearish
2
Neutral
0
Bullish
8
Key readings
- RSI (14)
- 72.32
- Bearish
- MACD (12,26,9)
- 8.54
- Bearish
- SMA (50)
- 109.99
- Bullish
- SMA (200)
- 54.41
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Zero base |
|---|---|
| 5Y | −14.28% |
| 3Y | −7.68% |
| 1Y | −57.06% |
| TTM | −17.64% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Turned to loss |
| 3Y | Loss widened by ₹4.06 Cr |
| 1Y | Loss widened by ₹2.07 Cr |
| TTM | Loss narrowed by ₹1.67 Cr |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Turned negative |
| 1Y | Outflow widened by ₹1.70 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | No sales |
|---|---|
| 5Y | −43.17 pp |
| 3Y | −44.68 pp |
| 1Y | −30.98 pp |
| TTM | −11.41 pp |
Revenue by year
| Mar 2017 | ₹0.00 Cr |
|---|---|
| Mar 2018 | ₹11.89 Cr |
| Mar 2019 | ₹11.99 Cr |
| Mar 2020 | ₹20.92 Cr |
| Mar 2021 | ₹26.17 Cr |
| Mar 2022 | ₹18.24 Cr |
| Mar 2023 | ₹15.39 Cr |
| Mar 2024 | ₹11.02 Cr |
| Mar 2025 | ₹28.20 Cr |
| Mar 2026 | ₹12.11 Cr |
Net profit by year
| Mar 2017 | −₹0.01 Cr |
|---|---|
| Mar 2018 | ₹0.00 Cr |
| Mar 2019 | ₹0.08 Cr |
| Mar 2020 | ₹0.43 Cr |
| Mar 2021 | ₹0.75 Cr |
| Mar 2022 | ₹0.14 Cr |
| Mar 2023 | −₹0.10 Cr |
| Mar 2024 | −₹5.75 Cr |
| Mar 2025 | −₹2.09 Cr |
| Mar 2026 | −₹4.16 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.4 | 4.07 | 1.33 | 4.26 | 7.82 | 9.28 | 6.28 | 4.83 | 1.94 | 2.53 | 4.33 | 3.31 | 8.22 |
| Expenses | 2.05 | 4.84 | 2.48 | 5.06 | 7.31 | 9.08 | 6.17 | 5.39 | 2.19 | 4.12 | 4.53 | 4.86 | 7.39 |
| Operating Profit | −0.65 | −0.77 | −1.15 | −0.8 | 0.51 | 0.2 | 0.11 | −0.56 | −0.25 | −1.59 | −0.2 | −1.55 | 0.83 |
| OPM % | −46.43% | −18.92% | −86.47% | −18.78% | 6.52% | 2.16% | 1.75% | −11.59% | −12.89% | −62.85% | −4.62% | −46.83% | 10.1% |
| Other Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.12 | 0.01 | −1.17 | 0.01 | 0.01 | 0.01 | 0.03 | 2.08 |
| Interest | 0.12 | 0.18 | 0.16 | 0.16 | 0.11 | 0.13 | 0.11 | 0.24 | 0.28 | 0.24 | 0.28 | 0.5 | 0.23 |
| Depreciation | 0.42 | 0.43 | 0.45 | 0.41 | 0.4 | 0.4 | 0.41 | −0.18 | 0.24 | 0.26 | 0.27 | 0.25 | 0.48 |
| PBT | −1.18 | −1.37 | −1.75 | −1.36 | 0.01 | −0.21 | −0.4 | −1.79 | −0.76 | −2.08 | −0.74 | −2.27 | 2.2 |
| Tax % | 0% | 0% | 0% | 6.62% | 0% | 0% | 0% | −16.76% | 0% | 0% | 0% | −74.45% | 0% |
| Net Profit | −1.18 | −1.37 | −1.75 | −1.45 | 0.01 | −0.22 | −0.39 | −1.49 | −0.76 | −2.08 | −0.73 | −0.58 | 2.2 |
| EPS (₹) | −3.15 | −3.66 | −4.68 | −3.88 | 0.03 | −0.59 | −1.04 | −3.98 | −2.03 | −5.56 | −1.95 | −1.55 | 5.88 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 28.2 | 12.11 | 18.39 |
| Expenses | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.94 | 15.75 | 20.9 |
| Operating Profit | −0.02 | −0.05 | −0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | −3.37 | 0.26 | −3.64 | −2.51 |
| OPM % | — | — | — | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | −30.58% | 0.92% | −30.06% | −13.65% |
| Other Income | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.1 | 0.09 | 0.06 | 0.04 | 0.05 | −1.03 | 0.05 | 2.13 |
| Interest | 0 | 0 | 0 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 | 1.24 | 1.25 |
| Depreciation | 0 | 0 | 0 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 | 1.01 | 1.26 |
| PBT | 0.04 | 0.01 | 0.01 | 0 | 0.1 | 0.73 | 1.21 | 0.31 | 0.04 | −5.65 | −2.39 | −5.84 | −2.89 |
| Tax % | 25% | 200% | 100% | — | 20% | 41.1% | 38.02% | 54.84% | 375% | 1.77% | −12.55% | −28.94% | — |
| Net Profit | 0.02 | 0 | −0.01 | 0 | 0.08 | 0.43 | 0.75 | 0.14 | −0.1 | −5.75 | −2.09 | −4.16 | −1.19 |
| EPS (₹) | 0.05 | 0 | −0.03 | 0 | 0.21 | 1.15 | 2 | 0.37 | −0.27 | −15.37 | −5.59 | −11.12 | −3.18 |
| Div. Payout % | 0% | — | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
| Reserves | 0.12 | 0.11 | 0.1 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.4 | −4.35 | −6.44 | −10.6 |
| Borrowings | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 8.09 | 12.06 |
| Other Liabilities | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.32 | 12.65 | 22.14 |
| Total Liabilities | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
| Fixed Assets | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.5 | 9.27 | 7.97 | 7.86 |
| CWIP | 0 | 0 | 0 | 0 | 3.33 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0.4 | 0.4 |
| Other Assets | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 10.38 | 19.79 |
| Total Assets | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −0.06 | 0 | −0.5 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | −0.2 | −0.66 | −2.36 |
| Investing | 0 | 0 | −0.19 | −4.23 | −3.41 | −2.4 | −3.15 | −1.53 | −0.94 | −1.59 | −0.7 | −0.9 |
| Financing | 0 | 0.1 | 0.56 | 1.14 | 3.1 | −0.23 | 0.4 | −0.91 | −0.04 | 1.43 | 1.4 | 3.81 |
| Net Cash Flow | −0.06 | 0.09 | −0.14 | 0.79 | 0.61 | 0.2 | 0.78 | −1.69 | −0.65 | −0.36 | 0.04 | 0.56 |
| Free Cash Flow | −0.06 | 0 | −0.69 | −0.35 | −2.49 | 0.42 | 0.38 | −0.78 | −0.61 | −1.79 | −1.36 | −3.26 |
| CFO/OP | 300 | 0 | 1,000 | 359 | 83 | 159 | 103 | 29 | 15 | 6 | −254 | 65 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.7 | 60.28 | 16.57 | 95.24 |
| Inventory Days | — | — | — | 203 | 279 | 88.17 | 107 | 155 | 287 | 124 | 56.09 | 290 |
| Days Payable | — | — | — | 609 | 645 | 312 | 269 | 300 | 310 | 383 | 173 | 530 |
| Cash Conversion Cycle | — | — | — | −346 | −331 | −166 | −139 | −131 | −8.57 | −199 | −101 | −145 |
| Working Capital Days | — | — | — | −59.86 | −71.84 | −56.18 | −48.26 | −36.02 | −0.47 | −116 | −54.23 | −200 |
| ROCE % | 0.81% | 0.2% | 0.19% | 0.66% | 1.56% | 8.4% | 14.34% | 6.13% | 3.67% | −58.39% | −12.06% | −76.6% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Parmax Pharma insights
60 extracted metrics across FY13–FY27.
Documents
- 14 Aug 2026
- 3 Jun 2026
- 17 Nov 2025
- General announcements 15 Oct 2026
Frequently Asked Questions about Parmax Pharma
What does Parmax Pharma Ltd do?
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.
Where is Parmax Pharma Ltd (PARMAX) listed?
Parmax Pharma Ltd trades under code 540359 on the BSE.
Which sector does Parmax Pharma Ltd belong to?
Parmax Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Parmax Pharma Ltd?
Over the last 52 weeks Parmax Pharma Ltd has traded between ₹22.6 and ₹139.1 as of 2 Nov 2026.
Company Information
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540359.md for Parmax Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.